Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BCTX BriaCell Therapeutics Corp
- Stocks
- Healthcare
- NASDAQ: BCTX
Price (delayed)
$2.07
Market cap
$14.03M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$8.32
Enterprise value
$1.57M
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
Highlights
BriaCell Therapeutics's quick ratio has soared by 200% from the previous quarter
The net income has shrunk by 67% QoQ
The EPS has dropped by 64% since the previous quarter and by 49% year-on-year
Key stats
What are the main financial stats of BCTX
Market
Valuations
Earnings
Shares outstanding
6.78M
Market cap
$14.03M
Enterprise value
$1.57M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.64
Price to sales (P/S)
N/A
EV/EBIT
0.37
EV/EBITDA
0.36
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$24.42M
Net income
-$19.62M
EBIT
$4.26M
EBITDA
$4.41M
Free cash flow
-$24.53M
Per share
Balance sheet
Liquidity
EPS
-$8.32
EPS diluted
-$8.32
Free cash flow per share
-$6.57
Book value per share
$3.22
Revenue per share
$0
TBVPS
$4.5
Total assets
$17M
Total liabilities
$5.06M
Debt
$0
Equity
$11.94M
Working capital
$10.45M
Debt to equity
0
Current ratio
3.41
Quick ratio
2.88
Net debt/EBITDA
-2.83
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-184%
Return on equity
-484.6%
Return on invested capital
N/A
Return on capital employed
33.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCTX stock price
How has the BriaCell Therapeutics stock price performed over time
Intraday
-1.9%
1 week
-28.87%
1 month
-40.35%
1 year
-86.29%
YTD
-75.56%
QTD
-29.59%
Financial performance
How have BriaCell Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$24.42M
Net income
-$19.62M
Gross margin
N/A
Net margin
N/A
The net income has shrunk by 67% QoQ
The company's operating income rose by 31% YoY and by 11% QoQ
Price vs fundamentals
How does BCTX's price correlate with its fundamentals
Growth
What is BriaCell Therapeutics's growth rate over time
Valuation
What is BriaCell Therapeutics stock price valuation
P/E
N/A
P/B
0.64
P/S
N/A
EV/EBIT
0.37
EV/EBITDA
0.36
EV/Sales
N/A
The EPS has dropped by 64% since the previous quarter and by 49% year-on-year
Efficiency
How efficient is BriaCell Therapeutics business performance
BCTX's ROA is down by 24% since the previous quarter
Dividends
What is BCTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCTX.
Financial health
How did BriaCell Therapeutics financials performed over time
BriaCell Therapeutics's quick ratio has soared by 200% from the previous quarter
The total assets has soared by 174% year-on-year and by 82% since the previous quarter
The debt is 100% smaller than the equity
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.